ProCE Banner Activity

Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response

Slideset Download
Conference Coverage
Factors associated with MRFS after TKI cessation included longer durations of imatinib therapy, MR4, and pretreatment IFN.

Released: December 09, 2016

Expiration: December 08, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen